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The anatomical connections of the subthalamic nucleus (STN)
have driven hypotheses about its functional anatomy, including
the hypothesis that the precise anatomical location of STN deep
brain stimulation (DBS) contributes to the variability of motor
and non-motor responses across patients with Parkinson’s
disease (PD). We previously tested the hypothesis using a
three-dimensional (3D) statistical method to interpret the acute
effects of unilateral DBS at each patient’s clinically optimized
DBS settings and active contact. Here, we report a similar
analysis from a new study in which DBS parameters were
standardized and DBS locations were chosen blind to clinical
response. In 74 individuals with PD and STN DBS, STN
contacts were selected near the dorsal and ventral borders
of the STN contralateral to the more affected side of the
body. Participants were tested off PD medications in each
of three unilateral DBS conditions (ventral STN DBS, dorsal
STN DBS and DBS off) for acute effects on mood, apathy,
working memory, response inhibition and motor function.
Voltage, frequency and pulse width were standardized,
and participants and raters were blind to condition. In
a categorical analysis, both dorsal and ventral STN DBS
improved mean motor function without affecting cognitive
measures. Ventral STN DBS induced greater improvement
in rigidity and anxiety than dorsal STN DBS. In the 3D
analysis, contact location was significant for body hypokinesia,
rigidity and resting tremor, with the greatest improvement
occurring with DBS in dorsal STN and zona incerta. The 3D
2018 The Authors. Published by the Royal Society under the terms of the Creative Commons
Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted
use, provided the original author and source are credited.




results provide new, direct functional evidence for the anatomically derived model of STN, in
which motor function is best represented in dorsal STN. However, our data suggest that functional
segregation between motor and non-motor areas of the STN is limited, because locations that induced
improvements in motor function and mood overlapped substantially.
1. Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disease [1]. PD varies in
its presentation; symptoms may include disturbed sleep, depressive symptoms, apathy and cognitive
complications in addition to classic motor features such as bradykinesia, rigidity and tremor [2].
Deep brain stimulation (DBS) of the subthalamic nucleus (STN DBS) can improve many of the motor
symptoms [3], but changes in mood, motivation and cognition also occur and may be either beneficial or
detrimental to the patient [4]. In fact, clinical results vary substantially among patients. Some evidence
suggests that the location of stimulation within or around the STN may contribute to the motor, mood
and cognitive effects of STN DBS, given its relatively segregated anatomical connections to motor,
somatosensory and limbic neural circuits [5]. However, the methods used to test this hypothesis in
the past have had limitations, including not examining the entire relevant volume of the brain [6–8],
not determining the statistical significance of relationships between behaviour and DBS site [9–12], or
not correcting for type 1 errors due to the multiple comparisons inherent in three-dimensional (3D)
statistical maps with many data points (i.e. voxels) [13]. Some studies examined the effects of DBS on
neuronal response with reference to the volume of tissue predicted to be activated based on electrical
field models [14]. We combined the anatomical location of the stimulated electrode with clinical data to
produce statistical images that demonstrate DBS locations associated with improvement and worsening
of each measured symptom, and determined overall statistical significance from these images using a
permutation approach [15]. This method avoids the issues noted above, and identifies whether location
relates to clinical response in a statistically rigorous manner controlled for multiple comparisons.
Using this method, we previously examined the acute effects of unilateral STN DBS in PD, using
each person’s clinically optimized stimulation parameters and electrode contacts. Mood, cognition and
motor function were assessed with DBS OFF and ON at least 8 h after the most recent dose of PD-related
medication. The 3D analyses suggested that location of stimulation was significantly associated with
mood, cognition and some motor outcomes [15]. Most motor measures improved with DBS everywhere
in the STN, while a few motor, cognitive and mood measures differed depending on the location of
stimulation. A limitation of that study was that stimulation parameters (e.g. voltage) differed across
individuals, which could differentially impact behaviour. The stimulation parameters used and the
contact chosen were determined through the clinical programming process, so the results could not
distinguish whether all participants would have had similar motor benefit with DBS anywhere in the
STN, or whether the ideal DBS location simply varied by participant. Therefore, in this new study,
all participants with PD had separate, blinded, unilateral stimulation conditions at both dorsal and
ventral STN locations chosen by brain imaging blind to clinical results. All stimulation parameters were
maintained across condition and participant. We hypothesized that our findings would be qualitatively
similar to those in our previous report, but that effects might be more striking due to the consistent
stimulation parameters and the more uniform approach to selecting DBS locations in both dorsal and
ventral STN.
2. Material and methods
2.1. Participants
Seventy-four patients with PD were recruited through the Movement Disorders Center at Washington
University St. Louis School of Medicine (WUSM), St. Louis, MO, USA. Inclusion criteria included
bilateral STN DBS therapy for clinically definite PD, as previously defined [16] based on established
criteria [17,18]. Patients waited at least 3 months after DBS implantation to participate in the study.
Exclusion criteria included neurological conditions such as history of stroke; history of serious head
injury (any neurological sequelae, open skull fracture or hospitalization); history of definite encephalitis
or oculogyric crises; drug-induced parkinsonism; sustained remission from PD; strictly unilateral
features after 3 years; supranuclear gaze palsy; cerebellar signs (ataxia of gait or limbs, central nystagmus,




Table 1. Demographics and clinical characteristics of 74 researchparticipantswithPD. CD-LD, carbidopa–levodopa; CD-LDER, carbidopa–
levodopa extended release; DA, dopamine; MAO, monoamine oxidase; COMT, catechol-O-methyl transferase, UDPRS, Unified Parkinson
Disease Rating Scale.
mean (s.d., range)
age (years) 62 (9.1, 43–80)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
education (years)a 15.1 (2.7, 10–20)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
disease duration (years) 12.4 (5.1, 0.51–26.5)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
time since STN DBS surgery (months) 18.2 (16.1, 3–77)
distribution
sex 50 male, 24 female
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ethnic originb 65 white, 4 Native American/Alaskan Native, 1 African American, 1
Asian, 2 unknown/other
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
more affected side, by UPDRS III subscore 41 right, 33 left
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
dominant handb 65 right, 7 left, 1 ambidextrous
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
current PD medicationc,d 74 CD-LD, 12 CD-LD ER, 33 DA agoniste, 7 MAO inhibitor, 32 COMT
inhibitor, 25 benzodiazepines, 40 amantadine, 7
antidepressantsf , 21 other drugs
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
aFour participants missing data.
bOne participant missing data.
cPrior to abstinence on the day of study.
dParticipant may appear in more than one medication category.
eNo participant was taking extended release formulations of DA agonists.
fAmitriptyline, bupropion, duloxetine, nortriptyline, trazodone.
scanning dysarthria or truncal ataxia); early severe autonomic involvement; early severe dementia
(within the first year of onset) with disturbances of memory, language and praxis; extensor plantar reflex;
Mini Mental State Examination score less than 24 [16]; any defect on brain imaging (such as infarcts, brain
tumour, hydrocephalus or congenital defects like lissencephaly but not cavum septum pellucidum); or
MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) exposure, for which patients were screened prior
to DBS surgery. The demographics of the participants of the study are shown in table 1.
2.2. Subthalamic nucleus deep brain stimulation electrode contact selection
The side of the brain contralateral to the more affected side of the body was stimulated. The more affected
side of the body was defined by the side of the body that had higher Unified Parkinson Disease Rating
Scale (UPDRS) scores in the off-medication, off-stimulation state [6]. The DBS electrode contacts for each
individual were placed in atlas space using a validated method [19,20] to identify the contact locations
with respect to the STN. Dorsal and ventral STN DBS contacts were chosen for each participant based
on the examination of their position in atlas space. Specifically, a contact within 2 mm of the ventral STN
border was chosen as the ventral contact, and a contact within 2 mm of the dorsal STN border was chosen
as the dorsal contact, ideally with one unused contact in between [6].
2.3. Stimulation protocol
Participants stopped PD medications at midnight before the morning of the study. The UPDRS ratings
and mood and cognitive tasks were completed during separate dorsal, ventral and OFF STN DBS
sessions over the course of one day. The order of the dorsal, ventral and OFF sessions was randomized
and blinded to the participants and raters. The voltage, frequency and pulse width were 2.5 V, 185 Hz
and 60 µs, respectively, for most participants. However, 14 participants experienced side effects from
2.5 V and so the voltage was reduced to 1.6–2.3 V.
2.4. Measurements
Motor symptoms were rated with the UPDRS, part III-motor, administered by a trained clinician blind
to stimulation condition. UPDRS subscale scores for bradykinesia (sum of scores from finger taps, hand




movements, rapid movement of hands and leg agility), rigidity, tremor at rest and total were summed
contralateral to the stimulated side of the brain. The UPDRS ‘body bradykinesia and hypokinesia’ item
score was considered separately (hereinafter ‘body’).
Cognition was evaluated via the spatial delayed response (SDR) and the Go/No-Go (GNG) tasks.
The SDR task assesses short-term and working memory for spatial information, and was performed
as described previously; the variable of interest was the distance between actual and recalled (after a
15 s delay) cue locations, or error [21,22]. The GNG task assessed the ability to select and inhibit a pre-
potent motor response appropriately under conditions of high pre-potent response strength [23], and
was performed as described previously [6]. The discriminability index, Pr, was the outcome measure,
defined as the proportion of hits minus the proportion of false alarms. Only data from participants who
reached a criterion of Pr > 0.5 in the OFF DBS condition were included in the analyses.
Self-rated current affective state was assessed using visual analogue scales (VASs) based on the
circumplex model of emotion [24] and transformed to valence and arousal scores, as described previously
[15,25]. Separate scores for anxiety and apathy were also measured using a VAS [8]. Higher scores on
valence, anxiety and apathy represented, respectively, happier, less anxious and less apathetic states.
2.5. Primary statistical analyses
2.5.1. Outliers
In the datasets for all measures in both statistical analyses—univariate and 3D—outliers were defined as
data values more than 3 s.d. from the mean. The datasets and statistical outcomes shown are based on
the datasets with these outliers removed.
2.5.2. Univariate statistics
Dorsal, ventral and OFF DBS scores for each measure, including total contralateral UPDRS, tremor at rest,
rigidity, bradykinesia, SDR error in mm, GNG Pr, valence, arousal, apathy and anxiety, were compared
using separate repeated-measures ANOVAs. If the ANOVA p-value was statistically significant, dorsal-
OFF, ventral-OFF and dorsal–ventral difference scores for the corresponding measures were compared
with 0 using one-sample t-tests. We repeated the ANOVAs for participants who received 2.5 V STN
DBS, excluding participants who received less than 2.5 V STN DBS. The threshold for statistical
significance for ANOVAs was α = 0.005, reflecting Bonferroni correction for multiple comparisons
(0.05/10 comparisons). The threshold for statistical significance for one-sample t-tests was α = 0.05.
2.5.3. Statistical mapping of deep brain stimulation effects to subthalamic nucleus anatomy
Our mapping method is described in detail in Eisenstein et al. [15]. Briefly, four statistical maps were
generated for each measure. (i) An N image shows the number of stimulated contacts that contributed
dorsal or ventral DBS difference scores to each voxel of the map, i.e. within 1.3 mm. Voxels with N< 6
were not included in further steps. (ii) A weighted mean image, containing the weighted mean difference
scores across participants, with nearer contacts weighted higher. (iii) A t image depicting weighted t
values derived from single-sample t tests comparing the mean difference scores (dorsal–OFF or ventral–
OFF) at each voxel with zero. (iv) A p-image containing p-values for the t test at each voxel. We
repeated the statistical mapping for participants who received 2.5 V STN DBS, excluding participants
who received less than 2.5 V STN DBS.
2.5.4. Type 1 error correction for multiple comparisons and sample bias
To test whether the anatomical location of the active DBS contact significantly contributed to clinical
effects, we used a permutation test as previously described [15]. Briefly, for each measure, a summary
score reflecting the extent and amplitude of significant voxels in the p-image was generated, and
compared with 1000 summary scores generated similarly but from randomly chosen pairings of the
active contact locations and difference scores. We considered a p-value ≤ 0.05 (i.e. a summary score
that would place it in the top 50 of the 1000 random data permutations) to indicate that DBS location
significantly contributed to a measure’s difference scores. We repeated type 1 error correction for
participants who received 2.5 V STN DBS, excluding participants who received less than 2.5 V STN DBS.




Figure 1. Distribution of contacts included in the analyses shown as green (dorsal) and purple (ventral) spheres, with paired contacts of
each participant indicated by yellow connecting rods, and blue transparent regions indicating the subthalamic nucleus (STN).
3. Results
3.1. Distribution of contacts
The stimulated contacts from 74 participants, each with a dorsal STN and ventral STN contact, are shown
in figure 1. All contacts were located within 2 mm of the STN border.
3.2. Univariate results
The effects of dorsal or ventral STN DBS on mood, cognitive and motor measures (irrespective of 3D
active contact location) are described in table 2. Ventral or dorsal DBS significantly improved all UPDRS
motor scores, anxiety, valence and apathy. Unilateral STN DBS did not significantly affect the mean scores
for the GNG and SDR cognition tests. Dorsal scores differed significantly from ventral scores for anxiety
and rigidity, which both improved more with ventral STN DBS than with dorsal STN DBS. Results were
similar when participants stimulated at less than 2.5 V were excluded from analyses, except that the
univariate effects of dorsal STN DBS did not differ significantly from those of ventral STN DBS on any
measure (electronic supplementary material, table 1).
3.3. Subthalamic nucleus deep brain stimulation effects depend on deep brain stimulation site
For the analysis based on 3D location of DBS, statistical significance for each measure is shown in table 3.
DBS location significantly contributed to the effects of STN DBS on body, rigidity and tremor at rest.
Statistical maps for these effects are shown in figure 2. Results were similar after excluding participants
who could not tolerate 2.5 V DBS.
4. Discussion
The results support the conclusion that 3D electrode contact location contributes to the motor effects
of STN DBS. The peak p-values for DBS-induced improvements in motor function were located more
dorsally in the STN. This confirms our findings in a different sample, using a different experimental
design [15], which showed greater motor improvement in dorsolateral STN, particularly for tremor at
rest. Similarly, previous studies also suggested greater improvement in motor function in dorsal STN and
the zona incerta (ZI) [10,26,27]. These results fit with anatomical data placing the dorsolateral portion of
the STN in a loop connecting primary motor cortex to putamen and motor thalamus, and linking the
zona incerta to motor and limbic systems.
In the current study, electrode contact site, as a 3D variable, did not significantly alter the effect of
STN DBS on cognitive or mood function in PD. However, ventral STN stimulation improved anxiety
more than dorsal STN stimulation in the univariate analysis. A previous study [28] showed increased
mood improvement with STN DBS in those with anxiety or mood disorders or higher symptom severity,




Table 2. Outcome measures, by STN DBS conditions and DBS site (dorsal versus ventral STN).




. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F2,138 = 13.7, p< 0.001* anxiety: dorsal versus OFF 6.2(16.0) 69 0.002
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
anxiety: ventral versus OFF 9.5(17.0) 69 <0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
anxiety: dorsal versus ventral −3.3(12.9) 69 0.04
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F2,138 = 1.9, p= 0.15 arousal: dorsal versus OFF 0(0.2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
arousal: ventral versus OFF −0.03(0.2) N/A N/A
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
arousal: dorsal versus ventral 0.03(0.1)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F2,138 = 11.1, p< 0.001* valence: dorsal versus OFF 0.1(0.2) 69 0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
valence: ventral versus OFF 0.2(0.3) 69 <0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
valence: dorsal versus ventral −0.05(0.2) 69 0.12
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F2,138 = 4.8, p= 0.009 apathy: dorsal versus OFF 7.1(20.8) 69 0.006
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
apathy: ventral versus OFF 6.3(23.7) 69 0.03
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
apathy: dorsal versus ventral 0.8(17.9) 69 0.7
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
cognitionb
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F2,132 = 1.5, p= 0.2 GNG: dorsal versus OFF 0.03(0.2) N/A N/A
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GNG: ventral versus OFF 0.01(0.2)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GNG: dorsal versus ventral 0.02(0.1)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F2,136 = 1.4, p= 0.2 SDR: dorsal versus OFF −1.0(8.5) N/A N/A
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SDR: ventral versus OFF −1.3(9.3)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SDR: dorsal versus ventral 0.33(9.31)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
movementc
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F2,138 = 30.9, p< 0.001* bradykinesia: dorsal versus OFF −1.6(2.1) 69 <0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
bradykinesia: ventral versus OFF −1.8(2.2) 69 <0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
bradykinesia: dorsal versus ventral 0.2(1.9) 69 0.8
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F2,140 = 27.1, p< 0.001* body: dorsal versus OFF −0.5(0.6) 70 <0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
body: ventral versus OFF −0.5(0.6) 70 <0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
body: dorsal versus ventral −0.01(0.6) 70 0.5
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F2,140 = 38.5, p< 0.001* rigidity: dorsal versus OFF −0.8(1.1) 70 <0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
rigidity: ventral versus OFF −1.1(1.2) 70 <0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
rigidity: dorsal versus ventral 0.3(0.9) 70 0.006
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F2,140 = 30.2, p< 0.001* tremor at rest: dorsal versus OFF −1.2(1.6) 70 <0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
tremor at rest: ventral versus OFF −1.2(1.8) 70 <0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
tremor at rest: dorsal versus ventral −0.01(1.1) 70 0.9
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F2,140 = 75.3, p< 0.001* UPDRS: total dorsal versus OFF −4.2(3.6) 70 <0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
UPDRS: total ventral versus OFF −4.2(3.5) 70 <0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
UPDRS: total dorsal versus ventral 0.02(2.7) 70 1.0
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
aFour VAS participants were statistical outliers and were omitted.
bOne GNG and 1 SDR participant were outliers and were omitted.
cThree UPDRS participants were outliers and were omitted.
*p-value survivesmultiple comparison correction (Bonferroni,α= 0.005). rmANOVA, repeated-measures ANOVA. All subjectswithmissing/incomplete
data in any measure were removed. Numbers in italics are all p-values less than 0.05.





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Weighted mean image (i), p-image (ii) and 3D p-image (iii) for measures with significant effect of contact location in the
3D analyses. (a) Body bradykinesia and hypokinesia item. (b) Rigidity. (c) Tremor at rest. For the weighted mean images, the cooler
shades indicatewhere, on average, the difference scores (ventral-OFF anddorsal-OFF) aremore negative (improvement relative toOFF, for
motormeasures). For the 2D p-image, warmer shades indicatemore significant p-values, while the cooler shades indicate less significant
p-values.White squares indicate peak coordinates. The 3D image is shownas viewed fromanteriorly, and the blue volume indicates values
less than 0.05 in the p-image. STN, subthalamic nucleus; ZI, zona incerta, D, dorsal, V, ventral, L, lateral, M, medial.
but psychiatric diagnosis was not assessed in the present study. The non-significant association of contact
location and cognitive function is surprising given the present sample size and our previous findings that
DBS effects on cognitive measures were location dependent [6,15]. However, there are several differences
between the current study and the most comparable previous study [15]. First, the previous study’s ON
sessions tested participants with their individually optimized DBS settings, including choice of active
contact. In other words, in that study the contact selection was not chosen blind to clinical response.
Furthermore, because in that study the contacts and settings were optimized clinically, cognitive or
affective responses may have contributed to selecting contact or pulse settings that were more likely to
improve mood or thinking than the anatomically chosen DBS contacts and standardized pulse settings
in the present study.




The strengths of this study include its relatively large sample size, acute stimulation paradigm,
assessment blind to the location stimulated and innovative statistical approach. Limitations include the
fact that clinical DBS electrode implantation targets the dorsal posterolateral STN, which necessarily
limits the number of contacts that fall in the anterior or medial–ventral STN. The limited number
of data points in these regions reflects this reality, reducing power in parts of the ventromedial and
anterior STN. Second, in some conditions, participants or examiners may have detected when STN
was turned on. However, as the focus of the study was the correlation of effect with DBS site, and
neither the participants nor the examiners knew the precise locations of the contacts, the study was
still blinded for the key variable under investigation, i.e. the location of the active contact. Third, the
minimum interval between DBS changes (42 min) was chosen based on previous experience with motor
signs, but there may be longer-term effects—on mood and cognitive function in particular—that this
investigation may have missed. However, the time limit on the OFF session was also chosen with ethical
and practical considerations in mind that preclude extending the time to study more delayed effects.
Finally, statistically significant changes in rating scales may not imply syndromal or clinically significant
changes. Nevertheless, UPDRS ratings are standard measures of parkinsonian severity, and VASs offer
one of the few practicable options for frequent assessment of emotional state. Self-report VAS ratings
have correlated well with clinical ratings of depression and anxiety severity [29–32].
Our previous study in a different sample of patients with PD did not support complete functional
segregation within the STN of mood, motor and cognitive function [15]. This new sample provides
some functional evidence for a dorsal–ventral, motor–non-motor gradient of benefit, in that the 3D
analysis found significant location effects for body, rigidity and tremor at rest (table 3), with the evidence
for improvement stronger in ZI or dorsolateral STN for these measures (table 3 and figure 2). By
contrast, anxiety improved significantly more with ventral than dorsal stimulation (table 2). On the other
hand, rigidity also improved more with ventral than dorsal stimulation (table 2); stimulation of either
ventral or dorsal STN improved motor function, anxiety, valence and apathy; and cognitive effects were
observed with neither stimulation site. Therefore, the direct, functional evidence supports only a mild
dorsal–ventral gradient for motor and non-motor effects of STN DBS, rather than a strict dorsal–ventral
functional segregation.
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